Shore Capital reaffirmed their hold rating on shares of AstraZeneca plc (LON:AZN) in a report issued on Tuesday, MarketBeat Ratings reports.

A number of other equities research analysts have also recently weighed in on the company. Jefferies Group LLC dropped their price target on AstraZeneca plc from GBX 4,400 ($56.91) to GBX 4,350 ($56.26) and set a hold rating for the company in a report on Thursday, August 24th. Liberum Capital reaffirmed a buy rating and set a GBX 4,800 ($62.08) price target on shares of AstraZeneca plc in a report on Monday, August 21st. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($50.44) price target on AstraZeneca plc and gave the company a sell rating in a report on Friday, August 18th. J P Morgan Chase & Co set a GBX 4,200 ($54.32) price target on AstraZeneca plc and gave the company a neutral rating in a report on Wednesday, August 9th. Finally, Investec raised AstraZeneca plc from a hold rating to a buy rating and dropped their price target for the company from GBX 5,000 ($64.67) to GBX 4,900 ($63.37) in a report on Wednesday, August 9th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of GBX 4,892.19 ($63.27).

AstraZeneca plc (AZN) opened at 4592.50 on Tuesday. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00. The firm’s market cap is GBX 58.14 billion. The firm’s 50-day moving average price is GBX 4,644.61 and its 200-day moving average price is GBX 4,870.16.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/astrazeneca-plc-azn-stock-rating-reaffirmed-by-shore-capital-2/1537359.html.

The firm also recently announced a dividend, which will be paid on Monday, September 11th. Shareholders of record on Thursday, August 10th will be issued a dividend of GBX 68.90 ($0.89) per share. The ex-dividend date is Thursday, August 10th. This represents a yield of 1.35%.

In other news, insider Nazneen Rahman purchased 39 shares of the business’s stock in a transaction dated Thursday, July 27th. The shares were bought at an average cost of GBX 4,370 ($56.52) per share, for a total transaction of £1,704.30 ($2,204.22).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.